Tyra shares drop more than 20% after Phase 2 bladder cancer results
Tyra Biosciences (TYRA) fell more than 20% in premarket trading after initial SURF302 Phase 2 results for its lead candidate dabogratinib in FGFR3-altered low bladder cancer patients.
Tyra Biosciences NASDAQ:TYRA fell more than 20% in premarket trading on Wednesday as investors reacted to initial results from a Phase 2 trial of its lead candidate, dabogratinib, in patients with a type of bladder cancer. The SURF302 trial was designed to evaluate dabogratinib in FGFR3-altered low…